Press coverage about Motus GI (NASDAQ:MOTS) has trended somewhat positive on Sunday, according to Accern. Accern rates the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Motus GI earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave news stories about the company an impact score of 48.6109500494805 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Shares of Motus GI traded up $0.24, reaching $5.99, during midday trading on Friday, according to Marketbeat. The company’s stock had a trading volume of 18,911 shares, compared to its average volume of 51,908. Motus GI has a fifty-two week low of $3.75 and a fifty-two week high of $10.66. The company has a market capitalization of $89.96 million and a PE ratio of -4.68.
Motus GI (NASDAQ:MOTS) last posted its quarterly earnings data on Tuesday, May 15th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.09). The firm had revenue of $0.01 million for the quarter. sell-side analysts predict that Motus GI will post -1.09 earnings per share for the current fiscal year.
In other Motus GI news, Director Gary E. Jacobs acquired 5,000 shares of the stock in a transaction dated Friday, May 18th. The shares were bought at an average cost of $5.24 per share, for a total transaction of $26,200.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
About Motus GI
Motus GI Holdings, Inc operates as a medical technology company to enhance the endoscopy outcomes and experiences in the United States and Israel. It focuses on the development and commercialization of the Pure-Vu system to enhance the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon.
Recommended Story: Average Daily Trade Volume – ADTV
Receive News & Ratings for Motus GI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motus GI and related companies with MarketBeat.com's FREE daily email newsletter.